AnaptysBio Inc (OQ:ANAB)

Aug 05, 2020 04:05 pm ET
AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jul 31, 2020 08:30 am ET
AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Jul 15, 2020 08:30 am ET
AnaptysBio Expands Executive Leadership Team
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Jul 08, 2020 04:05 pm ET
AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced...
Jul 02, 2020 08:48 pm ET
Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors' Losses?
SAN DIEGO, July 2, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of the companies listed below. ...
May 27, 2020 07:33 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 25, 2020 10:50 pm ET
ANAPTYSBIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against AnaptysBi
NEW ORLEANS, May 25, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio, Inc. (NasdaqGS: ANAB), if they purchased the Company's shares between October 10, 2017 and November 7, 2019, both dates inclusive (the "Class Period").  This action is pending in the United States District Court for the Southern District of California....
May 25, 2020 01:00 pm ET
ANAB DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds AnaptysBio, Inc. Shareholders with Losses in Excess of $100,000 of Class Action and Lead Plaintiff Deadline: May 26, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders...
May 25, 2020 10:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AnaptysBio, Inc. (ANAB)
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
May 22, 2020 10:50 pm ET
ANAPTYSBIO 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against AnaptysBi
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio, Inc. (NasdaqGS: ANAB), if they purchased the Company’s shares between October 10, 2017 and November 7, 2019, both dates inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
May 22, 2020 03:00 pm ET
DEADLINE ALERT for ANAB, DOYU, HAFC, and HFFG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 22, 2020 11:18 am ET
ANAB FINAL DEADLINE TUESDAY: ROSEN, A TOP RANKED INVESTOR FIRM, Reminds AnaptysBio, Inc. Investors of Important May 26 Deadline in Securities Class Action
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
May 21, 2020 05:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 21, 2020 03:00 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AnaptysBio, Inc. Investors (ANAB)
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired AnaptysBio, Inc. ("AnaptysBio" or "the Company") (NASDAQ:
May 21, 2020 01:00 pm ET
ANAB DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds AnaptysBio, Inc. Shareholders with Losses in Excess of $100,000 of Class Action and Lead Plaintiff Deadline: May 26, 2020
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AnaptysBio securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
May 21, 2020 12:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB)  investors who...
May 20, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017 -...
May 20, 2020 11:30 am ET
DEADLINE ALERT for XELA, ANAB, I, BBBY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 19, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB, BIDU, GRPN and LOPE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. AnaptysBio, Inc. (ANAB)Investors Affected: October 10, 2017 and November 7, 2019Lead Plaintiff Motion Deadline:...
May 19, 2020 04:34 pm ET
ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
NEW YORK, May 19, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
May 19, 2020 01:00 pm ET
ANAB DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds AnaptysBio, Inc. Shareholders with Losses in Excess of $100,000 of Class Action and Lead Plaintiff Deadline: May 26, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders...
May 18, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, LOPE, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017 - 11/7/2019Lead Plaintiff Motion Deadline: May 26,...
May 18, 2020 08:33 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AnaptysBio (ANAB) Investors: 8-DAY DEADLINE ALERT in Securities Class Action, Investors with Losses Should Contact its Attorneys
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  The May 26, 2020 lead plaintiff deadline in a securities fraud class action that has been filed against the company...
May 18, 2020 02:20 pm ET
ANAB INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Reminds AnaptysBio, Inc. Investors of Important May 26 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
May 17, 2020 12:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 15, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017 -...
May 15, 2020 03:45 pm ET
ANAPTYSBIO LOSS NOTICE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Reminds AnaptysBio, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $10
NEW YORK, May 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws....
May 14, 2020 09:27 am ET
ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (“Anaptys” or the “Company”) (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 13, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP) Class Period: shares issued in connection with its December 2019 Initial Public...
May 12, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB, BIDU and GRPN
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. AnaptysBio, Inc. (ANAB)Investors Affected: October 10, 2017 and November 7, 2019Lead Plaintiff Motion Deadline:...
May 12, 2020 07:35 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: TWO WEEK DEADLINE ALERT in Securities Fraud Class Action
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  The May 26, 2020 lead plaintiff deadline in a securities fraud class action that has been filed against the company...
May 12, 2020 11:30 am ET
DEADLINE ALERT for XELA, ANAB, I, BBBY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 11, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017...
May 10, 2020 11:57 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 08, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
May 08, 2020 11:30 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB)  investors who...
May 08, 2020 11:02 am ET
ANAPTYSBIO LOSS ALERT: ROSEN, A TOP RANKED FIRM, Reminds AnaptysBio, Inc. Investors to Contact Firm Prior to May 26 Deadline for Class Action Seeking Recovery of Investor Losses – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
May 06, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017 -...
May 06, 2020 04:05 pm ET
AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
May 05, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB and GRPN
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. AnaptysBio, Inc. (ANAB)Investors Affected: October 10, 2017 and November 7, 2019Lead Plaintiff Motion Deadline:...
May 05, 2020 11:30 am ET
DEADLINE ALERT for XELA, ANAB, I, BBBY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 04, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
May 03, 2020 01:15 pm ET
ANAB ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Investors of AnaptysBio, Inc. to Contact the Firm Prior to the Important Deadline in Suit Seeking Recovery of Investor Losses – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
May 01, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017 -...
May 01, 2020 01:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Apr 30, 2020 07:15 pm ET
ANAB LOSS NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Anaptysbio, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Con
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
Apr 30, 2020 11:30 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB) investors who...
Apr 29, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 29, 2020 07:26 pm ET
Shareholder Alert: Robbins LLP Announces It Is Investigating AnaptysBio, Inc. (ANAB) for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that it is investigating AnaptysBio, Inc. (NASDAQ: ANAB) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. AnaptysBio is a clinical stage biotechnology company that eng
Apr 28, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB, TLRY and WWE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Tilray, Inc. (TLRY) Investors Affected: January 15, 2019 - March 2, 2020Lead Plaintiff Motion Deadline: May 5,...
Apr 28, 2020 12:00 pm ET
RTIX & ANAB INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 27, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017 -...
Apr 24, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 23, 2020 10:35 am ET
ROSEN, A TOP RANKED LAW FIRM, Reminds AnaptysBio, Inc. Investors of Important Deadline in Securities Class Action – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff...
Apr 23, 2020 01:11 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Apr 22, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, IQ, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017...
Apr 22, 2020 04:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the F
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTI Surgical Holdings, Inc. (NADAQ: RTIX), AnaptysBio, Inc. (NASDAQ: ANAB),...
Apr 21, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALGN, ANAB, TLRY and WWE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Align Technology, Inc. (ALGN)Investors Affected: April 24, 2019 – July 24, 2019Lead Plaintiff Motion Deadline:...
Apr 20, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, BBBY, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 17, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, BBBY, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB) Class Period: 10/10/2017...
Apr 17, 2020 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB) investors who...
Apr 15, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP) Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 15, 2020 09:43 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980....
Apr 15, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the F
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTI Surgical Holdings, Inc. (NADAQ: RTIX), AnaptysBio, Inc. (NASDAQ: ANAB),...
Apr 15, 2020 12:12 pm ET
Zhang Investor Law Announces Securities Class Action Lawsuit Against AnaptysBio, Inc – ANAB
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”). If you wish to serve as lead...
Apr 14, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALGN, ANAB, TLRY and WWE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Align Technology, Inc. (ALGN)Investors Affected: April 24, 2019 – July 24, 2019Lead Plaintiff Motion Deadline:...
Apr 13, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, MESA INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: AnaptysBio, Inc. (ANAB)Class Period: 10/10/2017...
Apr 12, 2020 02:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
NEW YORK, April 12, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980....
Apr 12, 2020 02:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
NEW YORK, April 12, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NASDAQ: ANAB).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980....
Apr 10, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, MESA, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP) Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 10, 2020 08:15 pm ET
ANAB Loss Notice: Rosen, a Top Firm, Reminds AnaptysBio, Inc. Investors With Large Losses of the May 26 Deadline in the Class Action Seeking Recovery of Investor Losses – ANAB
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”), of the important May 26, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
Apr 10, 2020 01:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AnaptysBio, Inc. (ANAB)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
Apr 10, 2020 12:19 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Apr 09, 2020 12:37 pm ET
Shareholder Alert: Robbins LLP Reminds Investors AnaptysBio, Inc. (ANAB) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of AnaptysBio, Inc. (NASDAQ: ANAB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between October 10, 2017 and November 7, 2019. AnaptysBio is a clinical stage biotechnology company that e
Apr 08, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, SIX INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Six Flags Entertainment Corporation (SIX)Class...
Apr 08, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the F
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of RTI Surgical Holdings, Inc. (NADAQ: RTIX), AnaptysBio, Inc. (NASDAQ: ANAB),...
Apr 08, 2020 11:30 am ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AnaptysBio, Inc. (ANAB)
Law Offices of Howard G. Smith reminds investors of the upcoming May 26, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) securities between October 10, 2017 and November 7, 2019, inclusive (the “Class P
Apr 07, 2020 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANAB and XP
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. XP, Inc. (XP)Investors Affected: Shares issued in connection with the December 2019 initial public stock...
Apr 07, 2020 04:11 pm ET
ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for
NEW YORK and SAN DIEGO, April 7, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed in United States District Court for Southern District of California on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period")....
Apr 06, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: XP Inc. (XP)Class Period: shares issued in connection with its December 2019 Initial Public...
Apr 03, 2020 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANAB, SIX INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Six Flags Entertainment Corporation (SIX)Class...
Apr 02, 2020 08:44 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: Securities Fraud Class Action Filed, Important Deadlines Established
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  A securities class action has been filed, and certain investors may have valuable claims.  Class Period: Oct. 10,...
Apr 02, 2020 10:00 am ET
ANAB SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies AnaptysBio, Inc. Shareholders of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AnaptysBio securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 01, 2020 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANAB, SSL, XP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Sasol Limited (SSL) Class Period: 3/10/2015 - 1/13/2020Lead Plaintiff Motion Deadline: April 6,...
Apr 01, 2020 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exela Technologies, RTI Surgical, DouYu, and AnaptysBio and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Exela Technologies, Inc. (NADAQ: XELA), RTI Surgical Holdings, Inc. (NADAQ:...
Apr 01, 2020 06:23 pm ET
ANAPTYSBIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for
Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed in United States District Court for Southern District of California on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or "the...
Mar 31, 2020 07:15 pm ET
ANAB Stock: Berger Montague Investigates Securities Fraud Class Action Claims Against AnaptysBio, Inc. (NASDAQ: ANAB); Lead Plaintiff Deadline is May 26, 2020
PHILADELPHIA, March 31, 2020 /PRNewswire/ -- Berger Montague is investigating securities fraud claims against AnaptysBio, Inc. ("AnaptysBio" or the "Company") on behalf of all purchasers of AnaptysBio common stock (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019 (the "Class Period"). ...
Mar 31, 2020 07:00 pm ET
ANAPTYSBIO SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2020 to file lead plaintiff applications in a securities class action lawsuit against AnaptysBio, Inc. (NasdaqGS: ANAB), if they purchased the Company’s shares between October 10, 2017 and November 7, 2019, both dates inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of California.
Mar 31, 2020 11:15 am ET
ANAB LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against AnaptysBio, Inc.; Encourages Investors with Large Losses to Contact Firm – ANAB
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class...
Mar 31, 2020 10:00 am ET
ANAB SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies AnaptysBio, Inc. Shareholders of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
NEW YORK, March 31, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AnaptysBio securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/anab.        ...
Mar 30, 2020 11:01 pm ET
ANAPTYSBIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in AnaptysBio, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. (“Anaptys” or the “Company”) (NASDAQ:ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 30, 2020 03:00 pm ET
ANAB SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies AnaptysBio, Inc. Shareholders of Class Action and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the Company”) (NASDAQ: ANAB) and certain of its officers, on behalf of shareholders...
Mar 30, 2020 11:02 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Mar 27, 2020 07:45 pm ET
ANAB ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against AnaptysBio, Inc. - ANAB
NEW YORK, March 27, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws....
Mar 27, 2020 05:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of AnaptysBio, Inc. (ANAB) Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
Mar 27, 2020 04:14 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: Securities Fraud Class Action Filed
Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  A securities class action has been filed, and certain investors may have valuable claims.  Class Period: Oct. 10,...
Mar 27, 2020 03:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf AnaptysBio, Inc. (ANAB) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) securities between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”). AnaptysBio investors have until May 26, 2020 to fil
Mar 27, 2020 02:03 pm ET
Shareholder Alert: Robbins LLP Announces AnaptysBio, Inc. (ANAB) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of AnaptysBio, Inc. (NASDAQ: ANAB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between October 10, 2017 and November 7, 2019. AnaptysBio is a clinical stage biotechnology company that engages in develo
Mar 27, 2020 12:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of AnaptysBio Inc. Investors (ANAB)
The Law Offices of Frank R. Cruz announces an investigation on behalf of AnaptysBio Inc. ("AnaptysBio" or the "Company") (NASDAQ:
Mar 27, 2020 11:39 am ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against AnaptysBio, Inc. (ANAB)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB) in the United States District Court for the Southern District of California on behalf of those...
Mar 27, 2020 10:00 am ET
ANAB Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AnaptysBio, Inc. and Encourages Investors to Contact the Firm
NEW YORK, March 27, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB). Investors who purchased AnaptysBio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/anab. ...
Mar 27, 2020 09:00 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AnaptysBio, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AnaptysBio, Inc. (“AnaptysBio” or “the Company”) (NASDAQ:
Mar 27, 2020 07:46 am ET
AnaptysBio (ANAB) Class Action Alert: Johnson Fistel Encourages Investors to Contact Firm
Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB). The class action is on behalf of shareholders who...
Mar 26, 2020 09:21 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages AnaptysBio (ANAB) Investors Who Have Suffered Losses to Contact its Attorneys: Securities Fraud Class Action Filed
SAN FRANCISCO, March 26, 2020 /PRNewswire/ -- Hagens Berman urges investors in AnaptysBio, Inc. (NASDAQ: ANAB) who have suffered significant losses to submit their losses now.  A securities class action has been filed, and certain investors may have valuable claims.  ...
Mar 26, 2020 06:39 pm ET
ANAPTYSBIO ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AnaptysBio, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of investors that purchased AnaptysBio, Inc. (NASDAQ: ANAB) securities between August 10, 2017 and November 7, 2019 (the “Class Period”). Investors have until May 26, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 26, 2020 06:30 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AnaptysBio, Inc. (ANAB) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ:
Mar 26, 2020 04:44 pm ET
AnaptysBio (ANAB) Class Action Alert: Johnson Fistel Encourages Investors to Contact Firm
SAN DIEGO, March 26, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of AnaptysBio, Inc. ("AnaptysBio" or the Company")(NASDAQ: ANAB). The class action is on behalf of shareholders who purchased AnaptysBio common stock between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). If you wish to serve as lead plaintiff in this class action, you must move the Court no later than May 26, 2020. ...
Mar 26, 2020 04:40 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AnaptysBio, Inc. (ANAB) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) investors concerning the Company and its officers’ possible violations of federal securities laws.
Mar 26, 2020 03:08 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AnaptysBio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AnaptysBio, Inc. (“AnaptysBio” or “the Company”) (NASDAQ:
Mar 26, 2020 10:49 am ET
ANAB Stock - Class Action Lawsuit Filed Against AnaptysBio, Inc. on Behalf of Purchasers or Acquirers of ANAB Stock Between October 10, 2017 and November 7, 2019, Both Dates Inclusive - Kehoe Law Firm
PHILADELPHIA, March 26, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C. is making investors aware that a class action lawsuit was filed on March 25, 2020 in United States District Court, Southern District of California, against AnaptysBio, Inc. ("AnaptysBio" or the "Company") (NasdaqGS: ANAB) on behalf of individuals or entities who purchased, or otherwise acquired, ANAB securities between October 10, 2017 and November 7, 2019, inclusive (the "Class Period").  The securities class action was brought against AnaptysBio and certain of its current and former senior executives under Sections 10(b) and...
Mar 26, 2020 09:22 am ET
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against AnaptysBio, Inc. – ANAB
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for AnaptysBio investors under the federal securities laws.
Mar 25, 2020 08:55 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AnaptysBio, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AnaptysBio, Inc. (“AnaptysBio” or “the Company”) (NASDAQ:
Mar 02, 2020 08:45 am ET
AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported...
Feb 25, 2020 04:00 pm ET
AnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jan 08, 2020 04:00 pm ET
AnaptysBio to Present at J.P. Morgan Annual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Nov 08, 2019 08:05 am ET
AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30,...
Nov 08, 2019 08:00 am ET
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized,...
Sep 30, 2019 04:15 pm ET
AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topline data from an interim analysis of its...
Sep 27, 2019 06:30 am ET
AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Aug 08, 2019 04:15 pm ET
AnaptysBio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the second quarter ended June 30,...
Aug 06, 2019 06:30 am ET
AnaptysBio to Present at the Wedbush PacGrow 2019 Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jun 05, 2019 07:00 am ET
AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today presented updated proof-of-concept data for etokimab, its...
May 28, 2019 06:55 am ET
AnaptysBio to Present at the Jefferies 2019 Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
May 07, 2019 04:15 pm ET
AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the first quarter ended March 31,...
May 01, 2019 06:30 am ET
AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Mar 04, 2019 06:30 am ET
AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Feb 28, 2019 05:45 am ET
AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the fourth quarter and year ended...
Jan 02, 2019 06:30 am ET
AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Nov 26, 2018 08:00 am ET
Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ebix, Inc. (NASDAQ:EBIX), Gold Resource Corporation (NYSE:GORO), Mastech...
Nov 08, 2018 04:15 pm ET
AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30,...
Nov 05, 2018 06:30 am ET
AnaptysBio to Participate in Upcoming Investor Conferences
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Oct 08, 2018 07:30 am ET
Research Report Identifies AnaptysBio, Imperial Oil, Norbord, 3D, Apple Hospitality REIT, and Pinnacle Foods with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AnaptysBio, Inc. (NASDAQ:ANAB), Imperial Oil Limited (NYSE:IMO), Norbord...
Sep 28, 2018 04:05 pm ET
AnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option
AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its underwritten public offering of...
Sep 25, 2018 07:49 pm ET
AnaptysBio Announces Pricing of Public Offering of Common Stock
AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its underwritten public offering of...
Sep 24, 2018 04:01 pm ET
AnaptysBio Announces Proposed Public Offering of Common Stock
AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer $200.0 million of its common...
Sep 24, 2018 06:30 am ET
AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topline proof-of-concept data for etokimab, its...
Aug 07, 2018 06:30 am ET
AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the second quarter ended June 30,...
Aug 06, 2018 06:30 am ET
AnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jul 25, 2018 07:50 am ET
Report: Exploring Fundamental Drivers Behind Martin Midstream Partners, AnaptysBio, Bright Horizons Family Solutions, Masonite International, Digimarc, and Cohu — New Horizons, Emerging Trends, and Up
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Martin Midstream Partners L.P. (NASDAQ:MMLP), AnaptysBio, Inc....
May 30, 2018 06:30 am ET
AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
May 29, 2018 08:30 am ET
AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial of...
May 18, 2018 08:25 am ET
Market Trends Toward New Normal in Castlight Health, inc, Marriot Vacations Worldwide, AnaptysBio, Compass Diversified, Triumph, and Asbury Automotive Group — Emerging Consolidated Expectations, Analy
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Castlight Health, inc. (NYSE:CSLT), Marriot Vacations Worldwide...
May 08, 2018 04:15 pm ET
AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the first quarter ended March 31, 2018...
May 01, 2018 06:30 am ET
AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that clinical data for its ANB020 and ANB019 programs...
Apr 27, 2018 06:30 am ET
AnaptysBio To Participate in Upcoming Investor Conferences
SAN DIEGO, April 27, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that that company will participate in the following investor...
Mar 26, 2018 04:05 pm ET
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced top-line proof-of-concept data from an interim analysis of an...
Mar 20, 2018 07:40 am ET
Analysis: Positioning to Benefit within AnaptysBio, MoSys, CONMED, Franklin Financial Network, Hersha Hospitality Trust, and Inovalon — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AnaptysBio, Inc. (NASDAQ:ANAB), MoSys, Inc. (NASDAQ:MOSY),...
Mar 05, 2018 04:15 pm ET
AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones
ANB020 Top-Line Phase 2a Readouts Anticipated For Peanut Allergy in March 2018 and Eosinophilic Asthma in Second Quarter 2018
Feb 17, 2018 05:00 pm ET
AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial...
Feb 07, 2018 06:30 am ET
AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
SAN DIEGO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that data from the company’s Phase 2a trial of...
Jan 18, 2018 07:40 am ET
Investor Expectations to Drive Momentum within Martin Marietta Materials, AnaptysBio, Hope, Agilysys, Albany International, and Goldman Sachs BDC — Discovering Underlying Factors of Influence
NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Martin Marietta Materials, Inc. (NYSE:MLM), AnaptysBio,...
Jan 02, 2018 06:30 am ET
AnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will...
Nov 07, 2017 06:00 am ET
AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates
Announced Positive Proof-of-Concept Data for ANB020 in Atopic Dermatitis...
Nov 07, 2017 06:00 am ET
AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates
Announced Positive Proof-of-Concept Data for ANB020 in Atopic Dermatitis
Nov 06, 2017 04:15 pm ET
AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
Robust Half-Life and Extended Pharmacodynamic Activity Following a Single Dose of ANB019
Nov 06, 2017 04:15 pm ET
AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
Robust Half-Life and Extended Pharmacodynamic Activity Following a Single Dose of ANB019...
Oct 10, 2017 04:20 pm ET
AnaptysBio Files Registration Statement for Proposed Public Offering
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer and sell 3,000,000 shares of its common stock in an underwritten public offering. In addition, AnaptysBio intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offerin...
May 11, 2017 04:30 pm ET
AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported first quarter 2017 financial results and provided a pipeline update....
Apr 06, 2017 08:00 am ET
AnaptysBio Announces First-In-Human Dosing of ANB019
SAN DIEGO, April 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced first-in-human dosing of its wholly-owned proprietary anti-Interleukin-36 receptor (IL-36R) antibody, ANB019, in a healthy volunteer Phase 1 clinical trial. The double-blind, placebo-controlled, single and multiple ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB019 through subcutaneous and in...
Mar 08, 2017 04:30 pm ET
AnaptysBio Announces 2016 Operating Results and Pipeline Progress
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced progress on the Company’s product pipeline, business highlights and reported full year 2016 financial results....
Mar 04, 2017 03:00 pm ET
AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
SAN DIEGO, March 04, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that its scientific collaborators at the Benaroya Research Institute at Virginia Mason (BRI) have presented a translational research study entitled “Role of IL-33 in modulating human allergen-specific pathogenic CD4+T Cell responses,” at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting (Session Number 2604, Presentation Number ...
Jan 31, 2017 05:00 pm ET
AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Jan. 31, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares of common stock. The shares began trading on The NASDAQ Global Select Market on January 26, 2017 under the symbol “ANAB....
Jan 25, 2017 07:00 pm ET
AnaptysBio Announces Pricing of Initial Public Offering
SAN DIEGO, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on January 26, 2017, under the symbol "ANAB." In addition, AnaptysBio has granted the underwriters a 30-day option to purchase up to an additional 750,000 sha...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.